Wuhan Healthgen Biotechnology Corp 688765.SS

Last Updated: May 15, 12:00 AM·SSE

Wuhan Healthgen Biotechnology Corp

Wuhan Healthgen Biotechnology Corp. Stock Analysis 688765.SS

China Health Care Mid Cap
Wuhan Healthgen Biotechnology Corp. engages in the research, development in molecular pharmaceutical. The company is headquartered in Wuhan, Hubei and currently employs 253 full-time employees. The company went IPO on 2025-10-28. The firm's products mainly include drugs, pharmaceutical excipients, and scientific research reagents. The firm's pharmaceutical products mainly consist of recombinant protein series products with different specifications and requirements developed to meet different market demands, including recombinant human albumin products (pharmaceutical excipients, scientific research reagents), various recombinant protein products, and protease K products used for molecular diagnostics.
Read More
Lock image
crown-icon

Shariah Compliance Report

An extensive business and financial screening of the company which specifies why a stock is halal or haram!

Disclaimer

The content provided on this website is intended solely for informational and educational purposes. Musaffa is a technology, data, education, and research company. We are not licensed financial service provider by the authorized relevant financial service regulator in India or any other regulatory government body, and we do not offer or facilitate any trading, brokerage, investment, or financial advisory services. We do not deliberately target an audience seeking financial services.

By accessing this website, you acknowledge and confirm that you are seeking information relating to Musaffa of your own accord, and that there has been no form of solicitation, advertisement, or inducement by Musaffa or its members. Musaffa shall not be liable for the consequences of any action taken by relying on the material or information provided on this website. The contents of this website are the intellectual property of Musaffa.